Related Experiment Video
Updated: Nov 11, 2025
An Orthotopic Sciatic Nerve Xenograft for Neurofibromatosis Type 1 Neurofibromas
Published on: October 10, 2025
Crispr/Cas-based modeling of NF2 loss in meningioma cells
Natalie Waldt1, Christoph Kesseler1, Paula Fala2
1Department of Neuropathology, Otto-von-Guericke-University, Germany.
Background:
Alterations of the neurofibromatosis type 2 gene (NF2) occur in more than fifty percent of sporadic meningiomas. Meningiomas develop frequently in the setting of the hereditary tumor syndrome NF2. Investigation of potential drug-based treatment options has been limited by the lack of appropriate in vitro and in vivo models.
New Methods:
Using Crispr/Cas gene editing, of the malignant meningioma cell line IOMM-Lee, we generated a pair of cell clones characterized by either stable knockout of NF2 and loss of the protein product merlin or retained merlin protein (transfected control without gRNA).
Results:
IOMM-Lee cells lacking NF2 showed reduced apoptosis and formed bigger colonies compared to control IOMM-Lee cells. Treatment of non-transfected IOMM-Lee cells with the focal adhesion kinase (FAK) inhibitor GSK2256098 resulted in reduced colony sizes. Orthotopic mouse xenografts showed the formation of convexity tumors typical for meningiomas with NF2-depleted and control cells.
Comparison With Existing Methods:
No orthotopic meningioma models with genetically-engineered cell pairs are available so far.
Conclusion:
Our model based on Crispr/Cas-based gene editing provides paired meningioma cells suitable to study functional consequences and therapeutic accessibility of NF2/merlin loss.
Insights
Researchers developed a new model using CRISPR gene editing to study neurofibromatosis type 2 (NF2) in meningioma. This model helps investigate NF2/merlin loss and potential treatments for this brain tumor.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Neurofibromatosis type 2 (NF2) gene alterations are common in sporadic meningiomas.
- Meningiomas often arise in the context of the hereditary NF2 tumor syndrome.
- Lack of suitable in vitro and in vivo models hinders the investigation of drug-based treatments.
Purpose of the Study:
- To create a novel in vitro and in vivo model for studying meningiomas with NF2 alterations.
- To investigate the functional consequences of NF2/merlin loss in meningioma cells.
- To assess therapeutic strategies targeting NF2-deficient meningiomas.
Main Methods:
- Utilized CRISPR/Cas gene editing to generate NF2 knockout and control cell clones from the IOMM-Lee meningioma cell line.
- Compared the biological behavior of NF2-deficient and control meningioma cells.
- Established orthotopic mouse xenografts using these genetically engineered cell pairs.
Main Results:
- NF2-deficient meningioma cells exhibited reduced apoptosis and increased colony formation compared to controls.
- Inhibition of focal adhesion kinase (FAK) with GSK2256098 reduced colony size in non-transfected cells.
- Orthotopic xenografts recapitulated typical meningioma tumor formation.
Conclusions:
- A CRISPR/Cas-based gene editing approach successfully generated paired meningioma cell lines with and without NF2.
- This novel model enables the study of functional impacts and therapeutic targeting of NF2/merlin loss in meningiomas.
- The model addresses the unmet need for genetically engineered orthotopic meningioma models.
More Related Videos
09:39CRISPR-mediated Loss of Function Analysis in Cerebellar Granule Cells Using In Utero Electroporation-based Gene Transfer
Published on: June 9, 2018
04:01Author Spotlight: Modeling Brain Tumors In Vivo Using Electroporation-Based Delivery of Plasmid DNA Representing Patient Mutation Signatures
Published on: June 23, 2023